Cardiac monitoring of patients receiving arsenic trioxide therapy

• Published in: British journal of haematology 2004-03, Vol.124 (5), p.610-617
• Main Authors: Unnikrishnan, Dilip, Dutcher, Janice P., Garl, Susan, Varshneya, Nikita, Lucariello, Richard, Wiernik, Peter H.
• Format: Article
• Language: English
• Subjects: Adult; Aged; Antineoplastic Agents - adverse effects; Arrhythmias, Cardiac - chemically induced; Arsenic Trioxide; Arsenicals - adverse effects; Biological and medical sciences; cardiac function; Edema - chemically induced; Electrocardiography, Ambulatory; Female; fluid overload; Hematologic and hematopoietic diseases; Hematologic Neoplasms - drug therapy; Hematology; Humans; Male; Medical sciences; Middle Aged; Oxides - adverse effects; Prospective Studies; toxicity; ventricular tachycardia
• ISSN: 0007-1048; 1365-2141
• DOI: 10.1111/j.1365-2141.2003.04817.x

Summary Arsenic trioxide (ATO) is approved for the treatment of acute promyelocytic leukaemia and is under investigation for other malignancies. We report the cardiac findings in 18 patients with haematologic malignancies treated with ATO and assess the role of cardiac factors in fluid retention syndrome observed during ATO therapy. Based on initial observations in 10 patients treated with ATO, cardiac functions in the subsequent eight patients were evaluated prospectively. Evaluation included pre‐ and during‐treatment electrocardiograms, Holter monitoring, echocardiograms, multigated acquisition scan and cardiac stress tests if indicated. All eight patients developed fluid retention during ATO, evidenced by pulmonary congestion, oedema and pleural/pericardial effusions. No cardiac factors were identified that contributed to fluid retention. Six patients had prolonged corrected QT (QTc) compared with baseline, three developed ventricular tachycardia. Sinus tachycardia, ventricular premature contractions, and non‐sustained ventricular/supraventricular tachycardia were seen during ATO treatment. Fluid retention and cardiac events did not correlate with the dose or total amount of ATO or prior anthracycline therapy. In summary, fluid overload during ATO therapy does not appear to be cardiac in origin but appears to be drug‐related, and may reflect cytokine‐induced capillary leak. QTc prolongation, transient arrhythmias and clinically significant arrhythmias were seen with therapeutic doses of ATO.